FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113877029> ?p ?o ?g. }

• W2113877029 endingPage "25" @default.
• W2113877029 startingPage "20" @default.
• W2113877029 abstract "One of the most common autoimmune diseases is rheumatoid arthritis (RA), affecting 0.5–1% of the population. This systemic disease is marked by chronic inflammation of synovial joints, which leads to destruction of cartilage and bone and eventually to disability of the patient [1]. Though not directly lifethreatening, RA severely affects the quality of life of a patient and also has major economic consequences for society. Therefore, every attempt should be made to prevent the erosive processes to occur. Currently, the classification of RA relies mainly on the criteria described by the American College of Rheumatology (ACR) [2]. These criteria, originally formulated 50 yr ago and last adjusted in 1987, are based mainly on clinical parameters. Since these parameters are often only sufficiently fulfilled when the damaging effects of the inflammatory process are already in progress, this set of criteria is not very suitable for the early diagnosis of RA [3]. The key to early recognition of autoimmunity lies within the humoral immune system. Since blood samples are taken from clinic-visiting (pre-)patients, screening for serological RA-indicators can be performed quite easily. In the ACR criteria for RA one serological marker is included: rheumatoid factor (RF). The RF autoantibody system, directed against the Fc part of immunoglobulin (Ig) G molecules, has had a central role in the diagnosis and prognosis of RA during recent decades [4] because RF can be detected in the majority of RA patients. However, it is becoming more and more clear that the presence of RF is not restricted to patients with RA, but that it can also be detected in subsets of patients suffering from other diseases and even in a percentage of healthy (especially elderly) individuals [5]. The resulting lack of specificity for RA can lead to confusion and unwanted treatment. The shortcomings of the RF test have kept the search for more specific RA markers alive. Most autoantibody systems described during recent decades have failed to mature into mainstream tests for RA because of low sensitivity, lack of specificity or technical inconvenience, as reviewed previously [6–8]. The only antibody system that combines good sensitivity with superior specificity for RA is that targeting citrullinated epitopes. This review will focus mainly on the diagnostic potential of the second-generation anti-cyclic citrullinated peptide (CCP) test (CCP2) for RA. Next, we will address the prognostic ability of the anti-CCP test. The presence of these antibodies early in disease development opens a window of opportunity for early custom-tailored treatment of RA. Finally, we will review the effect of disease treatment on anti-CCP levels and briefly go into the putative functional role of these antibodies in the chronic aspects of RA." @default.
• W2113877029 created "2016-06-24" @default.
• W2113877029 creator A5018861128 @default.
• W2113877029 creator A5053894399 @default.
• W2113877029 creator A5081889079 @default.
• W2113877029 date "2005-09-27" @default.
• W2113877029 modified "2023-10-10" @default.
• W2113877029 title "Use and significance of anti-CCP autoantibodies in rheumatoid arthritis" @default.
• W2113877029 cites W131473268 @default.
• W2113877029 cites W1586192659 @default.
• W2113877029 cites W1590451869 @default.
• W2113877029 cites W1607571173 @default.
• W2113877029 cites W1921974465 @default.
• W2113877029 cites W1960483393 @default.
• W2113877029 cites W1969772641 @default.
• W2113877029 cites W1985763670 @default.
• W2113877029 cites W1990576071 @default.
• W2113877029 cites W2004208265 @default.
• W2113877029 cites W2005699747 @default.
• W2113877029 cites W2010247870 @default.
• W2113877029 cites W2011318612 @default.
• W2113877029 cites W2011465328 @default.
• W2113877029 cites W2013573826 @default.
• W2113877029 cites W2013990419 @default.
• W2113877029 cites W2018036031 @default.
• W2113877029 cites W2024988150 @default.
• W2113877029 cites W2034839671 @default.
• W2113877029 cites W2036916905 @default.
• W2113877029 cites W2043343045 @default.
• W2113877029 cites W2051941381 @default.
• W2113877029 cites W2052622082 @default.
• W2113877029 cites W2058481614 @default.
• W2113877029 cites W2076339488 @default.
• W2113877029 cites W2078964340 @default.
• W2113877029 cites W2082796552 @default.
• W2113877029 cites W2084515988 @default.
• W2113877029 cites W2096153127 @default.
• W2113877029 cites W2104854678 @default.
• W2113877029 cites W2105593250 @default.
• W2113877029 cites W2107005433 @default.
• W2113877029 cites W2108595441 @default.
• W2113877029 cites W2109578241 @default.
• W2113877029 cites W2115692677 @default.
• W2113877029 cites W2116287800 @default.
• W2113877029 cites W2117220283 @default.
• W2113877029 cites W2123361363 @default.
• W2113877029 cites W2123998087 @default.
• W2113877029 cites W2124313950 @default.
• W2113877029 cites W2126718956 @default.
• W2113877029 cites W2126928586 @default.
• W2113877029 cites W2133026816 @default.
• W2113877029 cites W2137052550 @default.
• W2113877029 cites W2140857612 @default.
• W2113877029 cites W2141045777 @default.
• W2113877029 cites W2141152363 @default.
• W2113877029 cites W2142862879 @default.
• W2113877029 cites W2147106132 @default.
• W2113877029 cites W2148078801 @default.
• W2113877029 cites W2149026148 @default.
• W2113877029 cites W2150915843 @default.
• W2113877029 cites W2151144931 @default.
• W2113877029 cites W2152348310 @default.
• W2113877029 cites W2152421927 @default.
• W2113877029 cites W2153805078 @default.
• W2113877029 cites W2154040419 @default.
• W2113877029 cites W2156444818 @default.
• W2113877029 cites W2160763791 @default.
• W2113877029 cites W2163824348 @default.
• W2113877029 cites W2164300339 @default.
• W2113877029 cites W2164744416 @default.
• W2113877029 cites W2168125040 @default.
• W2113877029 cites W2171896579 @default.
• W2113877029 cites W2319957449 @default.
• W2113877029 cites W2614112686 @default.
• W2113877029 cites W4236183098 @default.
• W2113877029 doi "https://doi.org/10.1093/rheumatology/kei111" @default.
• W2113877029 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16188946" @default.
• W2113877029 hasPublicationYear "2005" @default.
• W2113877029 type Work @default.
• W2113877029 sameAs 2113877029 @default.
• W2113877029 citedByCount "141" @default.
• W2113877029 countsByYear W21138770292012 @default.
• W2113877029 countsByYear W21138770292013 @default.
• W2113877029 countsByYear W21138770292014 @default.
• W2113877029 countsByYear W21138770292015 @default.
• W2113877029 countsByYear W21138770292016 @default.
• W2113877029 countsByYear W21138770292017 @default.
• W2113877029 countsByYear W21138770292018 @default.
• W2113877029 countsByYear W21138770292019 @default.
• W2113877029 countsByYear W21138770292021 @default.
• W2113877029 countsByYear W21138770292022 @default.
• W2113877029 countsByYear W21138770292023 @default.
• W2113877029 crossrefType "journal-article" @default.
• W2113877029 hasAuthorship W2113877029A5018861128 @default.
• W2113877029 hasAuthorship W2113877029A5053894399 @default.
• W2113877029 hasAuthorship W2113877029A5081889079 @default.
• W2113877029 hasBestOaLocation W21138770291 @default.
• W2113877029 hasConcept C159654299 @default.

• next